Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles

International Journal of Nanomedicine

Volumn 2, Issue 4, 2007, Pages 541-550

  Douziech Eyrolles, Laurence ^a,b   Marchais, Hervé ^a,b   Hervé, Katel ^a,b   Munnier, Emilie ^a,b   Soucé, Martin ^a,b   Linassier, Claude ^a,b   Dubois, Pierre ^a,b   Chourpa, Igor ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b IFR 135   (France)

Author keywords

Anticancer agent; Iron oxide nanoparticles; Magnetic drug targeting

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; FERRIC OXIDE; FOLIC ACID; IODINE 123; IRON 59; IRON OXIDE; MACROGOL; MAGNETITE; MITOXANTRONE; NANOCARRIER; NANOPARTICLE; POLYMER; SUPERPARAMAGNETIC IRON OXIDE; UNDECANOIC ACID;

BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MAGNETIC FIELD; NANOTECHNOLOGY; NONHUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; IRON; NANOMEDICINE; NANOPARTICLES; OXIDES;

EID: 50649125214     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Acar HY, Garaas RS, Syud F, et al. 2005. Superparamagnetic nanoparticles stabilized by polymerized PEGylated coatings. J Magn Magn Mater, 293:1-7.
2. Alexiou C, Arnold W, Hulin P, et al. 2001. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. J Magn Magn Mater, 225:187-93.
3. Alexiou C, Jurgons I, Schmid R, et al. 2003. Magnetic drug targeting - biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target, 11: 13 9-49.
4. Alexiou C, Jurgons R, Schmid R, et al. 2005. In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles. J Magn Magn Mater, 293:389-93.
5. Arias JL, Gallardo V, Gomez-Lopera SA, et al. 2001. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release, 77:309-21.
6. Asmatulu R, Zalich MA, Claus RO, et al. 2005. Synthesis, characterization and targeting of biodegradable magnetic nanocomposite particles by external magnetic fields. J Magn Magn Mater, 292:108-19.
7. Baird RD, Kaye SB. 2003. Drug resistance reversal - are we getting closer? Eur J Cancer, 39:2450-61.
8. Barratt GM. 2000. Therapeutic applications of colloidal drug carriers. Pharm Sci Technol Today, 3:163-71.
9. Bautista MC, Bomati-Miguel O, del Puerto Morales M, et al. 2005. Surface characterisation of dextran-coated iron oxide nanoparticles prepared by laser pyrolysis and coprecipitation. J Magn Magn Mater, 293:20-7.
10. Bazile D, Prud'homme C, Bassoullet MT, et al. 1995. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci, 84:493-8.
11. Bean CP, Livingston JD. 1959. Superparamagnetism. J Appl Phys, 30: 120S-9S.
12. Begent RHJ. 1999. Targeting cancer therapy. Brit J Cancer, 80:104-9.
13. Bergemann C, Müller-Schulte D, Oster J, et al. 1999. Magnetic ion-exchange nano- and microparticles for medical biochemical and molecular biological applications. J Magn Magn Mater, 194:45-52.
14. Butterworth MD, Illum L, Davis SS. 2001. Preparation of ultrafine silica- and PEG-coated magnetite particles. Colloid Surface A, 179:93-102.
15. Chourpa I, Douziech-Eyrolles L, Ngaboni-Okassa L, et al. 2005. Molecular composition of iron oxide nanoparticles, precursors for magnetic drug targeting, as characterized by confocal Raman microspectroscopy. Analyst, 130:1395-403.
16. De Cuyper M, Joniau M. 1988. Magnetoliposomes. Eur Biophys J, 15:311-9.
17. Deng Y, Wang L, Yang W, et al. 2003. Preparation of magnetic polymeric particles via inverse microemulsion polymerization process. J Magn Magn Mater, 257:69-78.
18. Emerich DF, Thanos CG. 2005. Nanomedicine. Current Nanoscience, 1:177-88.
19. Fauconnier N, Bée A, Roger J, et al. 1999. Synthesis of aqueous magnetic liquids by surface complexation of maghemite nanoparticles. J Mol Liq, 83:233-42.
20. Gomez-Lopera SA, Plaza RC, Delgado AV. 2001. Synthesis and characterization of spherical magnetiteibiodegradable polymer composite particles. J Colloid Interf Sci, 240:40-7.
21. Gupta AK, Curtis ASG. 2004. Surface modified superparamagnetic nanoparticles for drug delivery:interactions studies with human fibroblasts in culture. J Mater Sci: materials in medicine, 15:493-6.
22. Gupta AK, Gupta M. 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26:3995-4021.
23. Häfeli UO. 2004. Magnetically modulated therapeutic systems. Int J Pharm, 277:19-24.
24. Hong S, Leroueil PR, Janus EK, et al. 2006. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem, 17:728-34.
25. Huang PS, Oliff A. 2001. Drug targeting strategies in cancer therapy. Curr Opin Genet Dev, 11:104-10.
26. Hung CT, McLeod AD, Gupta PK. 1990. Formulation and characterization of magnetic polyglutaraldehyde nanoparticles as carriers for poly-1-lysine-methotrexate. Drug Dev Ind Pharm, 16:509-21.
27. Ibrahim A, Couvreur P, Roland M, et al. 1982. New magnetic drug carrier. J Pharm Pharmacol, 35:59-61.
28. Jeon SI, Andrade JD. 1991. Protein-surface interactions in the presence of polyethylene oxide. J Colloid Interf Sci, 142:159-66.
29. Kobayashi H, Matsunaga T. 1991. Amino-silane modified superparamagnetic particles with surface-immobilized enzyme. J Colloid Interf Sci, 141:505-11.
30. Kohler N, Fryxell GE, Zhang M. 2004. A bifunctional poly(ethyleneglycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J. Am. Chem. Soc. 126:7206-11.
31. Kohler N, Sun C, Wang J, et al. 2005. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir, 21:8858-64.
32. Kopecek J, Kopeckova P, Minko T, et al. 2000. HPMA copolymer-anticancer drug conjugates:design, activity, and mechanism of action. Eur J Pharm Biopharm, 50:61-81.
33. Kreuter J. 2004. Nanoparticles as drug delivery systems. Encyclopedia of Nanosciences and Nanotechnology, 7:161-80.
34. Lacava LM, Garcia VAP, Kückelhaus S, et al. 2004. Long-term retention of dextran-coated magnetite nanoparticles in the liver and spleen. J Magn Magn Mater, 272-276:2434-5.
35. Lee SJ, Jeong JR, Shin SC, et al. 2005. Magnetic enhancement of iron oxide nanoparticles encapsulated with poly(D,L-lactide-co-glycolide). Colloid Surf A: Physicochem Eng Aspects, 255:19-25.
36. (3) optics: Raman and XAS characterization. Opt Mater, 9:368-72.
37. Lübbe AS, Bergemann C, Huhnt W, et al. 1996. Preclinical experiences with magnetic drug targeting:tolerance and efficacy. Cancer Res, 56:4694-701.
38. Lübbe AS, Bergemann C, Riess H, et al. 1996. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res, 56:4686-93.
39. Lübbe AS, Alexiou C, Bergemann C. 2001. Clinical applications of magnetic drug targeting. J Surg Res, 95:200-6.
40. Lübbe AS, Bergemann C, Alexiou C. 2003. Targeting tumors with magnetic drugs. In Pagé M (ed). Cancer drug discovery and development:tumor targeting in cancer therapy. Totowa NJ: Humana Press Inc., p 379-88.
41. Maliksi L. 2006. Small is big business [online]. Mereatornet, 03 March 2006. Accessed 19 June 2006. URL:http://www.mercatornet.com Massart R. 1981. Preparation of aqueous magnetic liquids inalkaline and acidic media. IEEE Trans Magn, 17:1247-8.
42. Molday RS, Mackenzie D. 1982. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods, 52:353-67.
43. Müller RH, Maaßen S, Weyhers H, et al. 1996. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm, 138:85-94.
44. Müller JP, Gähde J, Mehner H, et al. 1999. Plasma-assisted transformation of iron surfaces into magnetite. Surf Coat Tech, 116-19:367-9.
45. Neuberger T, Schöpf B, Hofmann H, et al. 2005. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater, 293:483-96.
46. Ngaboni Okassa L, Marchais H, Douziech-Eyrolles L, et al. 2005. Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. Int J Pharm, 302:187-96.
47. Pardoe H, Chua-anusorn W, St Pierre TG, et al. 2001. Structural and magnetic properties of nanoscale iron oxide particles synthesized in the presence of dextran or polyvinyl alcohol. J Magn Magn Mater, 225:41-6.
48. Puisieux F, Barratt G, Couarraze G, et al. 1994. Polymeric micro- and nanoparticles as drug carriers. In Durnitriu S ed. Polymeric Biomaterials. New-York: Marcel Dekke, Inc., p 749-94.
49. Pulfer SK, Gallo JM. 2000. Targeting turnors using magnetic drug delivery. In Torrence PF ed. Biomedical chemistry: applying chemical principles to the understanding and treatment of disease. John Wiley and Sons, Inc., p 211-25.
50. Sachdeva MS. 1998. Drug targeting systems for cancer chemotherapy. Expert Opin Inv Drug, 7:1849-64.
51. Storm G, Belliot SO, Daemen T, et al. 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliver Rev, 17:31-48.
52. 3 nanoparticles. J Magn Magn Mater, 221:63-79.
53. Visscher GE, Robinson RL, Maulding HV, et al. 1985. Biodegradation and tissue reaction to 50:50 poly(D,L-tactide-co-glycolide) microcapsules. J Biomed Mater Res, 19:349-65.
54. Weetall HH. 1993. Preparation of immobilized proteins covalently coupled through silane coupling agents to inorganic supports. Appl Biochem Biotech, 41:157-88.
55. Whelan J, Mayenne F. 2006. Drug delivery:it's a small world. Chem Ind, 18-20.
56. Widder KJ, Flouret G, Senyei AE. 1979. Magnetic microspheres: synthesis of a novel parenteral drug carrier. J Pharm Sci, 68:79-82.
57. Widder KJ, Senyei AE, Ranney D. 1980. In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres. Cancer Res, 40:3512-17.
58. Widder KJ, Morris RM, Poore GA, et al. 1983. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur J Cancer Clin Oncol, 19:135-9.
59. Xu Z, Liu Q, Finch JA. 1997. Silanation and stability of 3-aminopropyl triethoxy silane on nanosized superparamagnetic particles:I. Direct silanation. Appl Surf Sci, 120:269-78.
60. Xu Z, Liu Q, Finch JA. 1999. Engineering of nanosize superparamagnetic particles for use in magnetic carrier technology. Surf Sci Series, 78:31-50.
61. Xu XQ, Shen H, Xu JR. 2005. Core-shell structure and magnetic properties of magnetite magnetic fluids stabilized with dextran. Appl Surf Sci, 252:494-500.
62. Zaitsev VS, Filimonov DS, Presnyakov IA, et al. 1999. Physical and chemical properties of magnetite and magnetite-polymer nanoparticles and their colloidal dispersions. J Colloid Interf Sci, 212:49-57.
63. Zhang Y, Kohler N, Zhang M. 2002. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 23:1553-61.